AG
CRL icon

Aperio Group’s Charles River Laboratories CRL Stock Holding History

Aperio Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$5.85M Buy
23,408
+37
+0.2% +$8.81K 0.02% 758
2020
Q3 		$5.29M Buy
23,371
+594
+3% +$123K 0.02% 718
2020
Q2 		$3.97M Sell
22,777
-269
-1% -$42.9K 0.01% 811
2020
Q1 		$2.91M Sell
23,046
-13
-0.1% -$1.95K 0.01% 856
2019
Q4 		$3.52M Buy
23,059
+450
+2% +$62.3K 0.01% 863
2019
Q3 		$2.99M Sell
22,609
-672
-3% -$90.1K 0.01% 890
2019
Q2 		$3.3M Sell
23,281
-343
-1% -$46.5K 0.01% 863
2019
Q1 		$3.43M Sell
23,624
-1,118
-5% -$147K 0.01% 822
2018
Q4 		$2.8M Sell
24,742
-664
-3% -$83.1K 0.01% 853
2018
Q3 		$3.42M Sell
25,406
-476
-2% -$58.7K 0.02% 816
2018
Q2 		$2.9M Buy
25,882
+233
+0.9% +$25.2K 0.01% 854
2018
Q1 		$2.74M Buy
25,649
+37
+0.1% +$3.99K 0.01% 862
2017
Q4 		$2.8M Buy
25,612
+739
+3% +$80.4K 0.01% 865
2017
Q3 		$2.69M Buy
24,873
+1,467
+6% +$151K 0.02% 827
2017
Q2 		$2.37M Buy
23,406
+1,236
+6% +$114K 0.01% 845
2017
Q1 		$1.99M Sell
22,170
-7
-0% -$595 0.01% 870
2016
Q4 		$1.69M Buy
22,177
+3,779
+21% +$287K 0.01% 890
2016
Q3 		$1.53M Sell
18,398
-4,790
-21% -$402K 0.01% 935
2016
Q2 		$1.91M Buy
23,188
+5,055
+28% +$416K 0.01% 825
2016
Q1 		$1.38M Buy
18,133
+2,470
+16% +$183K 0.01% 919
2015
Q4 		$1.26M Buy
15,663
+990
+7% +$71.4K 0.01% 913
2015
Q3 		$932K Buy
14,673
+4,143
+39% +$298K 0.01% 1004
2015
Q2 		$741K Buy
10,530
+2,024
+24% +$150K 0.01% 1117
2015
Q1 		$674K Buy
8,506
+517
+6% +$38.1K 0.01% 1114
2014
Q4 		$508K Buy
7,989
+1,569
+24% +$98.4K 0.01% 1214
2014
Q3 		$384K Sell
6,420
-262
-4% -$15K 0.01% 1263
2014
Q2 		$358K Buy
6,682
+2,010
+43% +$110K 0.01% 1294
2014
Q1 		$282K Buy
+4,672
New +$272K ﹤0.01% 1658
2013
Q4 		– Sell
-4,383
Closed -$220K – 1665
2013
Q3 		$203K Buy
+4,383
New +$201K ﹤0.01% 1641

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Aperio Group's CRL Position: Q4 2020 in Review

Aperio Group increased its Charles River Laboratories (CRL) stake by 0.16% in Q4 2020, buying an estimated $8.81K and bringing the position to 23,408 shares worth $5.85M. The position accounts for 0.02% of the portfolio, ranked #758.

Aperio Group first reported a position in CRL in Q3 2013 and has held it in 29 quarters since. 538 funds tracked by Wall St. Rank hold CRL as of Q4 2020.

  • Aperio Group held 23,408 shares of Charles River Laboratories worth $5.85M as of Q4 2020.
  • Aperio Group bought 37 Charles River Laboratories shares in Q4 2020, an estimated $8.81K.
  • Charles River Laboratories made up 0.02% of Aperio Group's portfolio in Q4 2020, its #758 holding.
  • Aperio Group first reported a position in Charles River Laboratories in Q3 2013 and has held it in 29 quarters since.
  • 538 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.